Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 3, Issue 1, 2009, Pages 17-23

  Rosenson, Robert S ^a   Helenowski, Irene B ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Blood viscosity; Fenofibrate; Lipid lowering therapy; Rheology; Very low density lipoprotein

Indexed keywords

FENOFIBRATE; FIBRINOGEN; PLACEBO; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID OXIDATION; MALE; METABOLIC SYNDROME X; MICROANGIOPATHY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHEAR RATE; VISCOMETER;

EID: 62749109648     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.10.004     Document Type: Article

References (26)

1. American Diabetes Association. Standards of medical care in diabetes-2007. Diab Care 30 Suppl. 1 (2007) S4-S41
2. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366 (2005) 849-861
3. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffit M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
4. Dintenfass L., and Sharp A. Inversion of the Fahraeus-Lindquist phenomenon in blood flow through capillaries of diminishing radius. Nature 215 (1967) 1099-1100
5. Pruzanski W. Viscosity and hyperviscosity: application of hemorheological concepts to rheumatology. J Rheumatol 12 (1985) 401-402
6. Pries A.R., Secomb T.W., Gessner T., Sperandio M.B., Gross J.F., and Gaehtgens P. Resistance to blood flow in microvessels in vivo. Circ Res 75 (1994) 904-915
7. Rosenson R.S., and Lowe G.D. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140 (1998) 271-280
8. Rosenson R.S., Shott S., and Tangney C.C. Hypertriglyceridemia is associated with an elevated blood viscosity. Atherosclerosis 161 (2002) 433-439
9. Leonhardt H., Arntz H.R., and Klemens U.H. Studies of plasma viscosity in primary hyperlipoproteinaemia. Atherosclerosis 28 (1977) 29-40
10. Seplowitz A.H., Chien S., and Smith F.R. Effects of lipoproteins on plasma viscosity. Atherosclerosis 38 (1981) 89-95
11. Rosenson R.S., Wolff D.A., Huskin A.L., Helenowski I.B., and Rademaker A.W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diab Care 30 (2007) 1945-1947
12. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
13. Tangney C.C., Hafner J.M., McQuiston B.D., Domas A.J., and Rosenson R.S. Postprandial changes in plasma and serum viscosity and plasma lipids and lipoproteins after an acute test meal. Am J Clin Nutr 65 (1997) 36-40
14. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
15. Rosenson R.S., McCormick A., and Uretz E.F. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem 42 (1996) 1189-1195
16. Matrai A., Whittington R.B., and Ernst E. A simple method of estimating whole blood viscosity at standardized hematocrit. Clin Hemorheol 7 (1987) 261-265
17. Rosenson R.S. Viscosity and ischemic heart disease. J Vasc Med Biol 4 (1993) 206-212
18. Dormandy J.A., and Guttridge J.M.C. Effect of clofibrate in blood viscosity in intermittent claudication. Br Med J 42 (1974) 259-262
19. Caimi G., Catania A., Francavilla G., Ramano A., SantonocitoG G., and Sarno A. Blood rheology changes during bezafibrate treatment. Br J Clin Pract 42 (1988) 456-458
20. Leschke M., Hoffken H., Schmidtsdorff A., Blanke H., Egbring R., Joseph K., et al. Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease. Dtsch Med Wochenschr 114 (1989) 939-944
21. Frost R.J., Geiss H.C., Otto C., Schwandt P., and Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 87 (2001) 44-48
22. Snyder L.M., Fortier N.L., Trainor J., Jacobs J., Leb L., Lubin B., et al. Effect of hydrogen peroxide exposure on normal human erythrocyte deformability, morphology, surface characteristics, and spectrin-hemoglobin cross-linking. J Clin Invest 76 (1985) 1971-1977
23. Bruch R.C., and Thayer W.S. Differential effect of lipid peroxidation on membrane fluidity as determined by electron spin resonance probes. Biochim Biophys Acta 733 (1983) 216-222
24. Goldstein B.D., Rozen M.G., and Amoruso M.A. Relation of fluorescence in lipid-containing red cell membrane extracts to in vivo lipid peroxidation. J Lab Clin Med 93 (1979) 687-694
25. Losada M., and Alio J.L. Malondialdehyde serum concentrations in type 1 diabetic with and without retinopathy. Doc Opthalmol 93 (1997) 223-229
26. Skrha J., Stule T., Hilgertova J., Weiserova H., Kvasnicka J., and Ceska R. Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol 493 (2004) 183-189